These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38685859)

  • 1. Pharmacogenomic Clinical Support Tools for the Treatment of Depression.
    Baum ML; Widge AS; Carpenter LL; McDonald WM; Cohen BM; Nemeroff CB;
    Am J Psychiatry; 2024 Jul; 181(7):591-607. PubMed ID: 38685859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
    Rosenblat JD; Lee Y; McIntyre RS
    J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.
    McCarthy MJ; Chen Y; Demodena A; Leckband SG; Fischer E; Golshan S; Suppes T; Kelsoe JR
    J Psychopharmacol; 2021 Aug; 35(8):992-1002. PubMed ID: 33938307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care.
    Saya S; Chondros P; Abela A; Mihalopolous C; Chatterton ML; Gunn J; Chen TF; Polasek TM; Dettmann E; Brooks R; King M; Spencer L; Alphonse P; Milton S; Ramsay G; Siviour Z; Liew J; Ly P; Thoenig M; Seychell R; La Rocca F; Hesson LB; Mejias N; Sivertsen T; Galea MA; Bousman C; Emery J
    Trials; 2023 May; 24(1):342. PubMed ID: 37208772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants for the treatment of depression in people with cancer.
    Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011006. PubMed ID: 29683474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM
    BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressants for the treatment of depression in people with cancer.
    Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011006. PubMed ID: 26029972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials.
    Brown LC; Stanton JD; Bharthi K; Maruf AA; Müller DJ; Bousman CA
    Clin Pharmacol Ther; 2022 Dec; 112(6):1303-1317. PubMed ID: 36111494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.
    Forester BP; Parikh SV; Weisenbach S; Ajilore O; Vahia I; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Shelton RC; Macaluso M; Li J; Traxler P; Logan J; Brown L; Dechairo B; Greden JF
    Am J Geriatr Psychiatry; 2020 Sep; 28(9):933-945. PubMed ID: 32513518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial.
    Xu L; Li L; Wang Q; Pan B; Zheng L; Lin Z
    J Affect Disord; 2024 Aug; 359():117-124. PubMed ID: 38762035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.
    Stäuble CK; Lampert ML; Allemann S; Hatzinger M; Hersberger KE; Meyer Zu Schwabedissen HE; Imboden C; Mikoteit T
    Trials; 2021 Dec; 22(1):919. PubMed ID: 34906208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.
    Islam F; Gorbovskaya I; Müller DJ
    Adv Exp Med Biol; 2021; 1305():231-255. PubMed ID: 33834403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times.
    Bättig VAD; Roll SC; Hahn M
    Pharmacopsychiatry; 2020 Jul; 53(4):185-192. PubMed ID: 32045941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
    Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
    Pharmacogenomics; 2019 Jan; 20(1):37-47. PubMed ID: 30520364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
    Oslin DW; Lynch KG; Shih MC; Ingram EP; Wray LO; Chapman SR; Kranzler HR; Gelernter J; Pyne JM; Stone A; DuVall SL; Lehmann LS; Thase ME; ; Aslam M; Batki SL; Bjork JM; Blow FC; Brenner LA; Chen P; Desai S; Dieperink EW; Fears SC; Fuller MA; Goodman CS; Graham DP; Haas GL; Hamner MB; Helstrom AW; Hurley RA; Icardi MS; Jurjus GJ; Kilbourne AM; Kreyenbuhl J; Lache DJ; Lieske SP; Lynch JA; Meyer LJ; Montalvo C; Muralidhar S; Ostacher MJ; Paschall GY; Pfeiffer PN; Prieto S; Przygodzki RM; Ranganathan M; Rodriguez-Suarez MM; Roggenkamp H; Schichman SA; Schneeweis JS; Simonetti JA; Steinhauer SR; Suppes T; Umbert MA; Vassy JL; Voora D; Wiechers IR; Wood AE
    JAMA; 2022 Jul; 328(2):151-161. PubMed ID: 35819423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder.
    Perlis RH; Dowd D; Fava M; Lencz T; Krause DS
    Depress Anxiety; 2020 Sep; 37(9):834-841. PubMed ID: 32383277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressants for the treatment of depression in people with cancer.
    Vita G; Compri B; Matcham F; Barbui C; Ostuzzi G
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD011006. PubMed ID: 36999619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.
    Machmutow K; Meister R; Jansen A; Kriston L; Watzke B; Härter MC; Liebherz S
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012855. PubMed ID: 31106850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.